AstraZeneca, in continued partnership with Bob Harper, a health and fitness expert, best-selling author and heart attack survivor, today announced the expansion of the Survivors Have Heart movement, taking its mission across the United States to unite heart attack survivors nationwide and elevate the importance of daily heart health management.
A new integrated analysis of Phase III data for FASENRA ® shows that patients with severe eosinophilic asthma who were continuously treated with the medicine for up to two years reduced their use of oral corticosteroids and experienced a sustained improvement in exacerbation rates, lung function, asthma control and health-related quality of life.
AstraZeneca will present new research across an industry-leading Oncology portfolio, including data for its transformational cancer medicines LYNPARZA ® and IMFINZI ® at the 2019 American Society of Clinical Oncology Annual Meeting in Chicago, May 31 to June 4, 2019.. In all, the Company will present 93 abstracts spanning multiple tumor types, including...
RNS Number: 6303 Y AstraZeneca PLC 10 May 2019 This announcement contains inside information. 10 May 2019 07:00 BST. Pooled analyses of the roxadustat global Phase III programme confirmed cardiovascular safety.
RNS Number: 3963 Y AstraZeneca PLC 08 May 2019 8 May 2019 14:00 BST. AstraZeneca PLC announces that, on 7 May 2019, it was notified by Marc Dunoyer, the Chief Financial Officer of the Company, that, on 7 May 2019, Mr Dunoyer purchased 8,500 Ordinary Shares of $0.25 each in the Company at a price of £58.00 per Share.. RNS is approved by the Financial Conduct Authority to...
AstraZeneca is teaming up with PGA golf champion Jason Day to encourage newly diagnosed Stage IV non-small cell lung cancer patients to ask their doctor about biomarker testing, which can help patients and their physician find the treatment options that are right for them. AstraZeneca is partnering with the world-renowned golf pro to launch the Test It Back...
RNS Number: 3675 Y AstraZeneca PLC 08 May 2019 8 May 2019 11:00 BST. AstraZeneca PLC today announced that Geneviève Berger, a Non-Executive Director of the Company, was re-elected as a director of L'Air Liquide S.A. for a term of four years following the conclusion of its Annual General Meeting of Shareholders, with effect from 7 May 2019.. RNS is approved by the...
RNS Number: 2913 Y AstraZeneca PLC 08 May 2019 8 May 2019 07:00 BST. Trastuzumab deruxtecan demonstrated clinically-meaningful response in. patients with refractory HER2-positive metastatic breast cancer, a population with high unmet need.
RNS Number: 1192 Y AstraZeneca PLC 07 May 2019 7 May 2019 07:00 BST. Calquence Phase III ASCEND trial met primary endpoint at interim analysis in relapsed or refractory chronic lymphocytic leukaemia and will stop early. The second is ELEVATE-TN in treatment-naïve, front-line CLL. Calquence is currently approved for the treatment of adults with relapsed or...
The oncology community gathered together last night to celebrate the winners of the first Cancer Community Awards. These awards recognize individuals and organizations who have created positive change in cancer care. The awards– a partnership between AstraZeneca and Scientific American Custom Media– includes nominations submitted by organizations...
RNS Number: 9632 X AstraZeneca PLC 03 May 2019 3 May 2019 07:00 BST. Qternmet XR approved in the US for the treatment of type-2 diabetes. The US Food and Drug Administration has approved Qternmet XR extended release tablets as an oral adjunct treatment to diet and exercise to improve glycaemic control in adults with type-2 diabetes..
The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6. 1. As at 30 April 2019 the issued share capital of AstraZeneca PLC with voting rights is 1,311,759,192 ordinary shares of US $0.25. The above figure for the total number of voting rights may be used by shareholders as the...
RNS Number: 7550 X AstraZeneca PLC 01 May 2019 1 May 2019 12:00 BST. AstraZeneca PLC announces that, on 29 and 30 April 2019, it was notified of transactions in the Company's ordinary shares of $0.25 each and American Depositary Shares by certain Persons Discharging Managerial Responsibilities of the Company as set out below. RNS is approved by the Financial...
RNS Number: 3645 X AstraZeneca PLC 29 April 2019 29 April 2019 07:00 BST. AstraZeneca and MSD Inc., Kenilworth, N.J., US today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion, recommending Lynparza as a 1st- line maintenance treatment of BRCA- mutated advanced ovarian cancer..
RNS Number: 3119 X AstraZeneca PLC 26 April 2019 26 April 2019 17:45 BST. Results of Annual General Meeting held on 26 April 2019. AstraZeneca PLC announced the results of the voting at its Annual General Meeting today.
AstraZeneca (AZN) reported a 14 per cent rise in product sales at constant currencies during the first quarter, boosted by a 59 per cent increase in global oncology sales. An improvement in operating margins meant core operating profit jumped by more than two-thirds to £$1.65bn. However, management said this year’s cash performance is expected to be adversely impacted by a number of one-off payments relating to prior business-development transactions, most of which were made during the first quarter. However, core operating profit is expected to be ahead of 2018 by a mid-teens percentage. Sell.
AstraZeneca Plc (AZN.L) Announced, in its interim results for the three months ended 31 March 2019, that revenues rose to $5.5 billion from $5.2 billion posted in the same period preceding year. The company's profit before tax stood at $758 million, compared to a profit of $374 million reported in the previous year. The basic earnings per share stood at $0.47, compared to earnings of $0.27 reported in the previous year.
Emerging Markets sales increased by 14%; China sales increased by 21%, with ex-China Emerging Markets also delivering strong growth at CER. US sales increased by 20%, while Europe sales declined by 12%. Japan sales increased by 26% to $501 m..
Emerging Markets sales increased by 14%; China sales increased by 21%, with ex-China Emerging Markets also delivering strong growth at CER. US sales increased by 20%, while Europe sales declined by 12%. Japan sales increased by 26% to $501 m..
AstraZeneca’s (AZN) cancer drug Lynparza has been approved in Europe for use in specific cases of advanced breast cancer. Astra’s executive vice president of oncology Dave Fredrickson says patients throughout the EU will now have access to a targeted and oral chemotherapy-free treatment option for a difficult-to-treat form of the disease. We remain sellers.
AstraZeneca Plc
AZN.L
AstraZeneca Plc
Bid
-
-
-
Ask
  • High
    -
  • OPEN
    -
  • VOL
    -
  • MKT CAP
    -m
  • LOW
    -
  • CLOSE
    -
  • AVG VOL
    -
  • SHARES IN ISSUE
    1.27B

Company Profile

A world-leading pharmaceutical group, AstraZeneca was created in 1999 via the merger of Sweden's Astra and the UK's Zeneca, which had been demerged from chemicals group ICI in 1993. About half of its total sales are generated from the US, with over a third of revenues coming from its gastrointestinal treatments such as Prilosec (Losec) and Nexium.

Classification

Market Indices-

Locations

HQ
Cambridge Biomedical Campus
1 Francis Crick Avenue
CB2 0AA
Cambridge
Watchlist